Pancreatic Adenocarcinoma

P2, N=29, Recruiting, University of Arizona | Trial completion date: Oct 2025 --> Jan 2026 | Trial primary completion date: Oct 2025 --> Jan 2026

P1, N=52, Recruiting, University of California, Davis | Not yet recruiting --> Recruiting | Trial completion date: Dec 2030 --> Feb 2030

P2, N=60, Not yet recruiting, Corcept Therapeutics

P=N/A, N=700, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026

Considering the prognostic implications of DLAT in tumors and its correlations with immune indicators, it is plausible to regard DLAT as both a prognosis feature for certain malignancies and an evaluative metric for immunotherapy efficacy. The findings suggest that DLAT could be a potential therapeutic target and serve as a biomarker for predicting patient outcomes and guiding treatment strategies in various cancers, with its prognostic and immunological implications likely to be context-dependent across different tumor types.

Cox regression and receiver operating characteristic analysis further indicated that KRT19 expression is an independent risk factor for OS, disease-specific survival, and progression-free interval in PAAD patients and can effectively distinguish tumor from normal tissue. In conclusion, the findings suggest that KRT19 could serve as a potential biomarker for the diagnosis and prognosis of PAAD, and it may be implicated in the regulation of the immune microenvironment.

Chemotherapy with gemcitabine and nab-paclitaxel was initiated, but the lesion persisted. Despite neoadjuvant chemotherapy, NTS occurred, indicating that this risk cannot be fully prevented. Surgical resection achieved disease control, underscoring the importance of vigilant follow-up and timely intervention in managing this rare but clinically significant complication.

While the precise mode of intercellular transfer remains to be elucidated, these findings suggest the involvement of extracellular vehicles or other secretory pathways. This strategy may offer a novel therapeutic avenue for targeting KRAS-driven tumors, particularly pancreatic adenocarcinoma.

The findings highlight the superior sensitivity and accuracy of SR-based detection in identifying EGFRvIII and capturing intratumor heterogeneity. SR-based analysis is recommended as the method for EGFRvIII detection in both clinical and research settings.

Furthermore, PTK6 was identified as a driver of PAAD proliferation, migration, and invasion. Collectively, our study elucidates TME-driven mechanisms of PAAD metastasis, identifies prognostic and therapeutic targets, and provides a framework for precision intervention.

P1, N=120, Active, not recruiting, NeoTX Therapeutics Ltd. | Recruiting --> Active, not recruiting

P1, N=10, Not yet recruiting, Northwell Health